Silence Therapeutics plc — Director's Dealing 2019

Oct 1, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4216O

Silence Therapeutics PLC

01 October 2019

Director/PDMR Shareholding and Additional Listing

October 1, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on September 28, 2019 1,626 Conditional Share Awards were exercised by Alistair Gray, Non-Executive Director of the Company, at a price of 5p per share.  Following this exercise, Alistair Gray is interested in 1,626 ordinary shares, being <0.01% of the enlarged issued share capital of the Company.

The Company also announces it has today issued and allotted 1,626 new ordinary shares of 5p each ("New Ordinary Shares") following this exercise of Conditional Share Awards under the 2018 Non-Employee Long Term Incentive Plan.  Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on October 7, 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 78,325,653. The Company holds no shares in Treasury.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Alistair Gray

2.

Reason for the notification

a)

Position / status

Non-Executive Director

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

b)

LEI

213800SSURRJBX85SQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares in Silence Therapeutics plc

ISIN for Silence Therapeutics plc Ordinary Shares:

GB00B9GTXM62

b)

Nature of the transaction

Exercise of share options over Ordinary Shares in Silence Therapeutics plc

c)

Prices(a) and volume(s)

Price	Volume
5p	1,626

d)

Aggregated information

- Aggregated volume

- Price

1,626 Ordinary Shares

£81.30

e)

Date of the transaction

28 September 2019

f)

Place of the transaction

Outside a trading venue

Enquiries:

Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
US IR Westwicke Partners Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHEAXEFEELNFFF